Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de fase I/IIa de SNK01 em participantes com doença de Alzheimer moderada

29 de setembro de 2026 atualizado por: NKGen Biotech, Inc.

Um estudo de Fase I/IIa para avaliar a segurança, tolerabilidade e eficácia exploratória de SNK01 em participantes com doença de Alzheimer moderada

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:

  1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
  2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

36

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Ontario
      • Ottawa, Ontario, Canadá, K1Z 1G3
        • Retirado
        • Ottawa Memory Clinic
    • California
      • Glendale, California, Estados Unidos, 91206
        • Recrutamento
        • Behavioral Research Specialists, LLC
        • Contato:
      • Santa Ana, California, Estados Unidos, 92705
        • Recrutamento
        • Syrentis Clinical Research
        • Contato:
      • Tarzana, California, Estados Unidos, 91356
        • Retirado
        • Valiance Clinical Research
    • Florida
      • Maitland, Florida, Estados Unidos, 32751
      • Orlando, Florida, Estados Unidos, 32804
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 07107
        • Recrutamento
        • Rutgers Health
        • Contato:
    • New York
      • Albany, New York, Estados Unidos, 12208
        • Recrutamento
        • Alzheimer's Disease Research Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

40 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).

  2. Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.

  3. Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

  4. Age 40 to 85 years old.

  5. Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.

  6. Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:

    1. Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
    2. Hormonal birth control for 30 days prior to administration of the study drug.
    3. A vasectomized sexual partner.
  7. Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.

  8. CDR-SB score of ≥ 9.5 and <16.0.

Exclusion Criteria:

  1. Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
  2. History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
  3. Any substance use disorder that has not been in remission for at least 12 months
  4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  5. Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
  6. History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
  7. Significant pulmonary disease predisposing to hypoxia.
  8. Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
  9. Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
  10. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
  11. Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
  12. Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
  13. Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
  14. Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
  15. Unstable/uncontrolled major depression or anxiety within the last 12 months.
  16. History of seizures in the past three years.
  17. Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
  18. Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
  19. Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
  20. Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
  21. Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
  22. Any contraindication for performing a brain MRI and/or Amyloid PET scan.
  23. Any participant whose safety the investigator considers to be at risk from this trial's intervention.
  24. Participants with any medically unstable/uncontrolled conditions.
  25. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  26. Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: SNK01

SNK01 will be administered as an IV infusion Q3W for up to 1 year.

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Comparador de Placebo: Placebo

Placebo will be administered as an IV infusion Q3W for up to 1 year.

Sodium Lactate Hartmann's Solution

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of participants with dose-limiting toxicity
Prazo: 3 weeks

DLTs will be assessed by the review of labs, PE and AEs

3 weeks
Maximum tolerated dose determination
Prazo: 3 weeks

Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D.

3 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Prazo: 1 Year

Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs

1 Year
Preliminary efficacy in cognitive assessment scores of CDR-SB
Prazo: 1 Year

Measure changes in cognitive assessment of CDR-SB from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of MMSE
Prazo: 1 Year

Measure changes in cognitive assessment of MMSE from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of NPI
Prazo: 1 Year

Measure changes in cognitive assessment of NPI from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
Prazo: 1 Year

Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
Prazo: 1 Year

Measure changes in cognitive assessment of ADAS-Cog from baseline

1 Year

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Prazo: 1 Year

Measure changes in CSF biomarkers as changed from baseline

1 Year
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Prazo: 1 Year

Measure changes in Plasma biomarkers as changed from baseline

1 Year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de novembro de 2023

Conclusão Primária (Estimado)

1 de março de 2028

Conclusão do estudo (Estimado)

1 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

6 de dezembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de janeiro de 2024

Primeira postagem (Real)

5 de janeiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • SNK01-AD01

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever